Cequent Pharmaceuticals

Manufacturing · United States · 11-50 Employees

View Company Info for Free

Overview

Headquarters

United States

Revenue

$13.8 Million

Industry

Manufacturing Pharmaceuticals Business Services Research & Development
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1

About Cequent Pharmaceuticals

Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. The company's pipeline includes combination therapies of oligonucleotide-based therapeutics and small molecules. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome). By its merger with IthenaPharma, Marina Biotech recently acquired IT-102/IT-103- next generation celecoxib - which will be developed together with CEQ508 as a therapeutic enhancer for therapies against FAP and CRC. IT-102/IT-103 are also being developed for the treatment of combined arthritis/ hypertension and treatment of pain requiring high dose of celecoxib.Explore more
Cequent Pharmaceuticals's Social MediaPopular SearchesCequent PharmaceuticalsMarina Biotech IncSIC Code 28,283NAICS Code 32,325Show more

Cequent Pharmaceuticals Org Chart

PhoneEmail
KC
United States flag for contact location.

Functional Analyst

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.

Is Cequent Pharmaceuticals your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Illustration of an envelope

Company Profile Activity

i

Among all Manufacturing companies

Low Activity

High Activity

Activity Insights

Cequent Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.

What does this means?

Cequent Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cequent Pharmaceuticals.

Cequent Pharmaceuticals financials insights

Gather financial insights about Cequent Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

2012

Stock Offering

$1.2M

See All Cequent Pharmaceuticals's Financials Insights

Cequent Pharmaceuticals Tech Stack

A closer look at the technologies used by Cequent Pharmaceuticals

Top Manufacturing Companies

Frequently Asked Questions Regarding Cequent Pharmaceuticals

What is Cequent Pharmaceuticals's official website?
Cequent Pharmaceuticals's official website is www.marinabio.com
What is Cequent Pharmaceuticals's Revenue?
Cequent Pharmaceuticals's revenue is $13.8 Million
What is Cequent Pharmaceuticals's SIC code?
Cequent Pharmaceuticals's SIC: 28,283
What is Cequent Pharmaceuticals's NAICS code?
Cequent Pharmaceuticals's NAICS: 32,325
How many employees does Cequent Pharmaceuticals have?
Cequent Pharmaceuticals has 11-50 employees
What industry does Cequent Pharmaceuticals belong to?
Cequent Pharmaceuticals is in the industry of: Manufacturing, Pharmaceuticals, Business Services
What companies has Cequent Pharmaceuticals acquired?
Cequent Pharmaceuticals has acquired the companies: Galenea, IthenaPharma, Symplmed Pharmaceuticals
What technology does Cequent Pharmaceuticals use?
Some of the popular technologies that Cequent Pharmaceuticals uses are: GoDaddy DNS, GoDaddy Email Hosting
What does Cequent Pharmaceuticals do?

Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. The company's pipeline includes combination therapies of oligonucleotide-based therapeutics and small molecules. The Marina Biotech pipeline currently includes a clin... ical program in Familial Adenomatous Polyposis (a precancerous syndrome). By its merger with IthenaPharma, Marina Biotech recently acquired IT-102/IT-103- next generation celecoxib - which will be developed together with CEQ508 as a therapeutic enhancer for therapies against FAP and CRC. IT-102/IT-103 are also being developed for the treatment of combined arthritis/ hypertension and treatment of pain requiring high dose of celecoxib.Read More

What are Cequent Pharmaceuticals social media links?
Cequent Pharmaceuticals Linkedin page Cequent Pharmaceuticals Twitter page
Is Cequent Pharmaceuticals a public company?
Cequent Pharmaceuticals is private company therefore does not currently have an official ticker symbol
See more information about Cequent Pharmaceuticals

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.